ArticleJournal of innate immunity2022
The Dynamics of Circulating Heparin-Binding Protein: Implications for Its Use as a Biomarker.
Article in Journal of innate immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Kinetics and prognostic value of heparin binding protein at the ST-segment-elevation myocardial infarction.Annals of medicine · 2026Article
- Heparin-Binding Protein and Transplant-Associated Inflammation: Emerging Roles in Infection, Ischemia-Reperfusion Injury, and Allograft Dysfunction.Journal of clinical medicine · 2026Review
- Diagnostic Value of Heparin-Binding Protein (HBP) in Pulmonary Infection After Radical Surgery for Lung Cancer: A Retrospective Study.Health science reports · 2026Article
- The influence of early serum heparin-binding protein (HBP) levels on the occurrence of sepsis in patients with severe burns.Journal of medical biochemistry · 2026Article
- "WBC-HBP Dissociation" Unveils Occult Xanthogranulomatous Inflammation Mimicking Hepatocellular Carcinoma in Diabetic Patients.Journal of hepatocellular carcinoma · 2026Article
- Heparin-binding protein as an emerging host-response biomarker for periprosthetic joint infection: a narrative review.Frontiers in cellular and infection microbiology · 2026Review
- Plasma Heparin-Binding Protein as a Predictor of Functional Recovery and a Potential Therapeutic Target in Acute Anterior Circulation Large-Vessel Occlusion Stroke.Brain sciences · 2025Article
- Heparin Binding Protein in Sepsis-A Comprehensive Overview of Pathophysiology, Clinical Usage and Utility as Biomarker.Biomedicines · 2025Review
- Heparin-Binding Protein in Cerebrospinal Fluid as a Biomarker for Bacterial Meningitis: A Study of Diagnostic Accuracy.Annals of neurology · 2025Article
- Optical Bionanosensors for Sepsis Diagnostics.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Heparin-binding Protein as a Diagnostic and Prognostic Marker of Infections: A Systematic Review and Meta-analysis.Mediterranean journal of hematology and infectious diseases · 2025Review
- The potential role of heparin-binding protein in neonatal sepsis: research progress.Frontiers in cellular and infection microbiology · 2024Review
- Hematologic cancers and infections: how to detect infections in advance and determine the type?Frontiers in cellular and infection microbiology · 2024Review
- A First Computational Frame for Recognizing Heparin-Binding Protein.Diagnostics (Basel, Switzerland) · 2023Article
- Heparin-Binding Protein: A Prognostic Biomarker Associated with Severe or Complicated Community-Acquired Pneumonia in Children.Journal of inflammation research · 2023Article
- Dynamic changes in heparin-binding protein as a prognostic biomarker for 30-day mortality in sepsis patients in the intensive care unit.Scientific reports · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin-binding protein (HBP) is a promising biomarker for the development and severity of sepsis. To guide its use, it is important to understand the factors that could lead to false-positive or negative results, such as inappropriate release and inadequate clearance of HBP. HBP is presumably released only by neutrophils, and the organs responsible for its elimination are unknown. In this study, we aimed to determine whether non-neutrophil cells can be a source of circulating HBP and which organs are responsible for its removal. We found that in two cohorts of neutropenic patients, 12% and 19% of patients in each cohort, respectively, had detectable plasma HBP levels. In vitro, three leukemia-derived monocytic cell lines and healthy CD14+ monocytes constitutively released detectable levels of HBP. When HBP was injected intravenously in rats, we found that plasma levels of HBP decreased rapidly, with a distribution half-life below 10 min and an elimination half-life of 1-2 h. We measured HBP levels in the liver, spleen, kidneys, lungs, and urine using both ELISA and immunofluorescence quantitation, and found that the majority of HBP was present in the liver, and a small amount was present in the spleen. Immunofluorescence imaging indicated that HBP is associated mainly with hepatocytes in the liver and monocytes/macrophages in the spleen. The impact of hematologic malignancies and liver diseases on plasma HBP levels should be explored further in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.